Xenitra Limited · ASX:XEN
Xenitra — Investor Presentation (May 2026)
20 slides from Xenitra's investor presentation, May 2026
Slide 1: Investor Presentation May 2026
Investor Presentation May 2026
Slide 2: Disclaimer
Disclaimer The information contained in this presentation has been prepared by Xenitra Limited ACN 150 110 017 (Company). This presentation contains summary information about the current activities of the Company and its subsidiaries as at the date of this presentation. The information in this pres
Slide 3: Growing the world's best brands in Asia with authentic products
Growing the world’s best brands in asia with authentic products and scaling with loyal customers ASX : XEN 3
Slide 4: Corporate Snapshot
Corporate Snapshot CAPITAL STRUCTURE Top 20 Holders: 49% Share Price: 0.4c 3,862,858,827 Market Cap: $15m 1,036,285,358 $70m+ 25+ Total Sales since 15,000,000 Brand Partners 2024 948,500,000 200+ 50+ RWA-Tokenised TOTAL: 5,862,644,185 (3,294 holders) Online Storefronts Distributors ASX : XEN 4
Slide 5: The Rebrand Explained: A new name. A new chapter.
The Rebrand Explained A new Xenitra reflects the company's modernised vision — connecting premium Global FMCG Brands with high-growth Asian consumer markets. Our growth strategy is based on three name. product-tailored sales channels: Nutritional product trading, Online and Hospital OTC Medicine Sal
Slide 6: Insights from a $70m+ trusted Asian sales ecosystem
Xenitra has earned some crucial insights by creating & operating a $70m+ trusted Asian sales ecosystem for international brands allowing us to expand into the exciting new segments of OTC Medicine and RWA-Tokenisation. ASX : XEN 6
Slide 7: Brands in our ecosystem now
Brands in our ecosystem now ASX : XEN
Slide 8: Three core segments in our growth strategy
Xenitra has now focused on three core segments in our growth strategy; — Nutritionals — OTC Medicine — Real World Asset (RWA) Tokenisation ASX : XEN 8
Slide 9: Nutritionals, OTC Medicine, RWA Tokenisation
Nutritionals OTC Medicine RWA Tokenisation Summary Summary Summary The evolution of the historical daigou New channel that is opening due to Blockchain enabled closed sales based selling model that has evolved regulatory relaxation in China, driven by ecosystem leveraging existing online and across
Slide 10: Nutritionals Business has been revitalised
Nutritionals Business has been revitalised ASX : XEN 10
Slide 11: Q3 sales jump 300% quarter-on-quarter
Q3 sales jump 300% quarter-on-quarter. APRIL 2026 - Q3 FY26 QUARTERLY SALES UPDATE Preliminary unaudited results confirm strongest quarter since restructuring began. $8.3m +300% $4m+ $70m+ Q3 total sales QoQ growth vs Q2 March sales alone Lifetime sales since 2024 Full sales recovery to historical h
Slide 12: $30m Danone partnership with Rockcheck
$30m Danone partnership with Rockcheck. MARCH 2026 DEAL AT A GLANCE $30m AUD revenue target Two agreements formalise and significantly expand Xenitra's most important B2B relationship. 140m RMB equivalent 1 Danone Product Sales Agreement • Targets ~$30m AUD (140m RMB) in Danone product sales to Rock
Slide 13: Cross Border OTC Medicines: The next big thing
Cross Border OTC Medicines The next big thing ASX : XEN 13
Slide 14: OTC medicines channel now operational
OTC medicines channel now operational APRIL / MAY 2026 Hong Kong Fukang Trading Co. acquired for A$100,000 enabling a fast start into the ecommerce channel with established sales, warehousing and team members experienced in cross border OTC Medicine Sales in Greater China. A significant new growth o
Slide 15: RWA Tokenisation
RWA Tokenisation Real products, Real consumers, Real-world assets —tokenised ASX : XEN 15
Slide 16: OPAL Token Ecosystem
OPAL Token Ecosystem Product PROCUREMENT REVENUE MODEL tokenisation Contracted offtake secured directly from brand owner by XEN under agreed supply terms. Tokenised products sold by XEN at high margin, generating the capital base for the reserve. XEN distributes and tokenises products (e.g. EZZ) Tok
Slide 17: RWA Tokenisation launched, validated, and now in the market
RWA Tokenisation launched, validated, and now in the market ASX : XEN 17
Slide 18: OPAL Token Ecosystem gaining rapid traction
OPAL Token Ecosystem APRIL OPAL Token / MAY gaining 2026 in less than one month rapid traction OPAL Token Launched and Key General Manager On Board First three weeks: >$320k in EZZ product sales >56 distributors onboarded • EZZ Life Sciences first brand integrated — $10m, 4-year global distribution
Slide 19: Experienced Board and Senior Management Team
Experienced Board and Senior Management Team Dr Anthony Noble Ms Zhao (Tracy) Zhang Chairman of the Board of Directors Head of China Doctor of Philosophy, Master of Business Administration, Bachelor of Science Bachelor of Information Technology and Master of Accounting Anthony has extensive Board an
Slide 20: Key Takeaways
Key Takeaways • Xenitra has the strongest established channel to market in China of any Australian listed entity with $39m is Sales in FY25 and more than $70m in sales since 2024. • Rebranded company with a new and focused strategy driving high margin growth. • Whole company streamlined yielding sig